Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
A Guidi, C Codecà, D Ferrari - Medical Oncology, 2018 - Springer
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
[PDF][PDF] Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
A Guidi, C Codecà, D Ferrari - Medical Oncology, 2018 - researchgate.net
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
A Guidi, C Codecà, D Ferrari - Medical Oncology, 2018 - search.proquest.com
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
A Guidi, C Codecà, D Ferrari - Medical oncology …, 2018 - pubmed.ncbi.nlm.nih.gov
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
A Guidi, C Codecà, D Ferrari - Medical Oncology (Northwood …, 2018 - europepmc.org
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
A Guidi, C Codecà, D Ferrari - Medical Oncology, 2018 - search.proquest.com
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …